No Data
Humacyte Insider Sold Shares Worth $2,364,521, According to a Recent SEC Filing
EF Hutton Initiates Coverage On Humacyte With Buy Rating, Announces Price Target of $25
EF Hutton Initiates Humacyte(HUMA.US) With Buy Rating, Announces Target Price $25
EF Hutton analyst Jason Kolbert initiates coverage on $Humacyte(HUMA.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success rate of 33.2% and
Humacyte Price Target Maintained With a $15.00/Share by Benchmark
Benchmark Co. Remains a Buy on Humacyte (HUMA)
Humacyte to Participate at Upcoming Investor Conferences in September